Programs – Publication Format
CMS would absorb 340B drug discount program under leaked HHS reorganization proposal
340B, Centers for Medicare and Medicaid Services, HHS, reorganization, Programs – Publication Format, proposal – intent, drug discount program, United States Health Resources and Services Administration, CMS, Policy, Leaked, Changing
Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire
Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support
Vigil Neuroscience, VG-3927, Alzheimer’s disease, Phase 1 clinical trial, Sanofi strategic investment, TREM2 agonist program, Microglia therapy
Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials
Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program
Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law
340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption
Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients
Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action
340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner